| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash (used in) provided by financing activities, continuing operations | -3,201 | -1,882 |
| Net decrease in cash, cash equivalents, and restricted cash, continuing operations | -9,356 | -6,197 |
| Net increase in cash and cash equivalents, discontinued operations | 11,151 | 11,111 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash, consolidated | 1,795 | 4,914 |
| Cash and cash equivalents at beginning of period | 907 | - |
| Cash and cash equivalents at end of period | 2,702 | - |
NovaBay Pharmaceuticals, Inc. (NBY)
NovaBay Pharmaceuticals, Inc. (NBY)